Why Immunic, Inc.’s (IMUX) Stock Is Down 7.94%
As of Thursday, November 05, Immunic, Inc.’s IMUX share price has dipped by 7.94%, which has investors questioning if this is right time to buy.Tudor Pop
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
Tudor Pop
Jenna Brashear
Rosalio Madrigal
Michael Rose
Rosalio Madrigal
| Share Statistics | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $98.6 | $202.9 | 23% |
|
| Shares Out (Mil) | 42.8 | 55.4 | 44% |
|
| Institutional Ownership | 98.4% | 92.9% | 78% |
|
| Float (Mil) | 12.0 | 40.7 | 22% |
|
| Beta | na | 1.04 | na |
|
| Avg Daily Volume (000s) | 190 | 566 | 43% |
|
| Price Change (52-week) |
1.5% | 41.0% | 52% |
|
| Growth | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | na | 13.2% | na |
|
| Net Income (5yr) | (17.2%) | (10.3%) | 23% |
|
| EPS (5yr) | 26.0% | 15.8% | 77 |
|
| Dividends (5yr) | na | 0.0% | na |
|
| Cash Flow (5yr) | (15.1%) | (15.7%) | 51% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 7 | 6 | 11 | |
| Current EPS | ($0.759) | ($3.598) | ($2.394) | |
| Month Ago EPS | ($0.816) | ($3.568) | ($2.427) | |
| # Rev Up | 1 | 1 | 1 | |
| # Rev Down | 0 | 1 | 1 | |
| Three Months Ago EPS | ($0.859) | ($3.687) | ($2.506) | |
| Year/Year Chg | (23.3%) | (42.3%) | (60.3%) | |
| Financials | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | na | $39 | na |
|
| Net Income (TTM) (Mil) | ($128) | ($44) | 9% |
|
| EPS (TTM) | ($3.803) | ($1.400) | 9% |
|
| Operating Cash Flow (TTM) (Mil) | ($96) | ($34) | 6% |
|
| Net Cash Flow (TTM) (Mil) | $97 | ($1) | 77% |
|
| Long-Term Debt (Q1) (Mil) | $0 | $4 | 0% |
|
| Enterprise Value (Q1) (Mil) | ($29) | $144 | 1% |
|
| Valuation | IMUX | Industry Median |
Percentile (All Stocks) |
|
| P/B | 1.10 | 1.97 | 31% |
|
| P/E | na | 17.5 | na |
|
| Dividend Yield | na | 0.0% | na |
|
| PEG (5yr hist) | na | 0.8 | na |
|
| Ratios | IMUX | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | na | 67.6% | na |
|
| Net Margin | na | (50.6%) | na |
|
| ROA | (144.9%) | (47.4%) | 3% |
|
| ROE | (223.2%) | (53.5%) | 4% |
|
| Liabilities to Assets | 23.4% | 29.7% | 16% |
|
| F-Score | 3 | 3 | 18% |
|
Immunic, Inc. did not pass any screens on 11/16/2026.
Price and market data provided by QuoteMedia and delayed a minimum of 15 minutes unless otherwise indicated. Fundamental data provided by AAII's Stock Investor Pro and S&P Global Market Intelligence and are updated through the previous trading day.
Ⓒ 2026 American Association of Individual Investors